Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9101–9150 of 75562
Each of Andrew Spaventa, the Company’s Chief Executive Officer and Chair of the Company’s Board, Eli Glezer, Ph.D., the Company’s Chief Scientific Officer and Dalen Meeter, the Company’s Chief Financial Officer resigned from the Company, effective as of immediately prior to the Effective Time.
Immediately following the Effective Time, the Company’s board of directors (the “Board”) was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa.
Immediately following the Effective Time, Joshua Stahl was appointed as the Company’s Chief Executive Officer and Jason Myers was appointed as the Company’s President.
Immediately following the Effective Time, the Company’s board of directors (the “Board”) was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa.
Each of Andrew Spaventa, the Company’s Chief Executive Officer and Chair of the Company’s Board, Eli Glezer, Ph.D., the Company’s Chief Scientific Officer and Dalen Meeter, the Company’s Chief Financial Officer resigned from the Company, effective as of immediately prior to the Effective Time.
Immediately following the Effective Time, the Company’s board of directors (the “Board”) was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa.
Each of Andrew Spaventa, the Company’s Chief Executive Officer and Chair of the Company’s Board, Eli Glezer, Ph.D., the Company’s Chief Scientific Officer and Dalen Meeter, the Company’s Chief Financial Officer resigned from the Company, effective as of immediately prior to the Effective Time.
Immediately following the Effective Time, Joshua Stahl was appointed as the Company’s Chief Executive Officer and Jason Myers was appointed as the Company’s President.
Immediately following the Effective Time, the Company’s board of directors (the “Board”) was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa.
Immediately following the Effective Time, the Company’s board of directors (the “Board”) was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa.
Each of Andrew Spaventa, the Company’s Chief Executive Officer and Chair of the Company’s Board, Eli Glezer, Ph.D., the Company’s Chief Scientific Officer and Dalen Meeter, the Company’s Chief Financial Officer resigned from the Company, effective as of immediately prior to the Effective Time.
Immediately following the Effective Time, the Company’s board of directors (the “Board”) was re-constituted to consist of the following directors: Andrew ElBardissi, Avi Kometz, Bryan Sendrowski, Joshua Stahl, Jason Meyers and Andrew Spaventa.
On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.
appointed Toby Srihiran Brown, Executive Vice President and Global Head of Reinsurance of the Company, as the Company’s interim Chief Accounting Officer, to be effective as of March 15, 2025
elected Christian Mumenthaler a director of the Company and appointed Mr. Mumenthaler to its Finance and Risk Committee and its Investment Committee, effective May 1, 2025.
Tamara L. Schock, notified the Company of her intent to resign as Executive Vice President and Chief Accounting Officer of the Company.
Ms. Spofford has agreed to extend her retirement date to April 30, 2025
On February 27, 2025, J.Jill, Inc. (the “Company”) announced that it has appointed Mary Ellen Coyne to serve as the Company’s Chief Executive Officer and President to succeed the Company’s current Chief Executive Officer and President, Claire Spofford, following Ms. Spofford’s previously disclosed decision to retire.
Ms. Coyne will also fill the vacancy on the Company’s Board of Directors as a result of Ms. Spofford’s retirement.
On February 26, 2025, the Board of Directors of Masco Corporation (the “Company”) elected Heath M. Eisman, 50, as the Company’s Vice President, Controller and Chief Accounting Officer, effective February 27, 2025.
On February 13, 2025, Liu Yu resigned from his position as Chief Operating Officer, Chief Scientific Officer and Head of Research of Graphjet Technology (the “Company”), effective immediately.
On February 27, 2025, the Company terminated the employment of Jorge Aldecoa as the Company’s Chief Product Officer, effective immediately.
On February 21, 2025, the Board of Directors of the Company (the “Board”) appointed Xi (Jacob) Cao to serve as the Company’s Chief Operating Officer, effective February 21, 2025.
On February 21, 2025, Tao Han notified Maison Solutions Inc. (the “Company”) of his resignation as Chief Operating Officer of the Company, effective immediately.
On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.
On February 23, 2025, Garth Graham resigned from the Board of Directors (the “ Board ”) of ModivCare Inc. (the “ Company ”), effective as of February 28, 2025.
On February 26, 2025, John A. Forbes resigned as a member of our Board of Directors.
On February 24, 2025, Marc Zandman resigned from the board of directors of Vishay Precision Group, Inc., a Delaware corporation (the “Company”), effective immediately before the election of directors at the Company’s annual meeting of stockholders, which is expected to be held on May 21, 2025
Christa Mitchell, Chief Strategy Officer of Pineapple Financial Inc. (the “Company”), notified the Company that she would resign as Chief Strategy Officer, effective March 7, 2025.
appointed Don Kim as Chief Financial Officer of the Company, effective as of March 27, 2025.
accepted the resignation of Thomas Hess as Chief Financial Officer of the Company, effective as of March 26, 2025.
On February 24, 2025, Deborah Macdonald notified Kinder Morgan, Inc. (“KMI”) that she will retire from KMI’s Board of Directors (the “Board”) at the end of her current term and consequently will not stand for re-election to the Board at KMI’s 2025 annual meeting of stockholders in May (the “2025 Annual Meeting”).
Effective February 26, 2025, Adrian I. Peace will no longer serve in the role of President, Performance Technologies for Modine Manufacturing Company (the "Company") and will terminate employment with the Company on September 30, 2025.
On February 24, 2025, Michael D. Cahill, VWF Bancorp Inc.'s (the "Company") President and Chief Executive Officer, a member of the Board of Directors of the Company, the Company's subsidiary GreenWay Bank's (the "Bank") President and Chief Executive Officer, and a member of the Board of Directors of the Bank, notified the Company and the Bank that he will retire from the Company and the Bank, at the end of the current term of his employment agreement, effective December 31, 2025.
On February 27, 2025, the Company announced that Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel & Secretary of the Company will step down from her positions at the Company effective March 7, 2025.
On February 25, 2025, the Board of Directors (the “Board”) of Louisiana-Pacific Corporation (the “Company”) appointed Kelly H. Barrett as a director of the Company.
On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025.
The Board appointed Clayton Main as a director of the Company to fill the vacancy created by Mr. Priore’s resignation to be effective April 1, 2025.
On February 26, 2025, John V. Priore provided to the Board of Directors (the “Board”) notification of his resignation from the Board of Priority Technology Holdings, Inc. (the “Company”), effective April 1, 2025.
On February 27, 2025, the Board of Directors filled the vacancy created by Mr. Morgan’s retirement by appointing Rob Buchner as a Class III member of the Board of Directors.
On February 27, 2025, Charles Morgan notified the Company of his retirement, effective immediately, from his position as a Class III member of the Company’s Board of Directors and from his positions as Lead Independent Director, Chairman of the Nominating and Corporate Governance Committee and member of the Audit Committee.
On February 25, 2025, the Company’s Board of Directors appointed Navam Welihinda as Elastic’s Chief Financial Officer, effective as of February 28, 2025, to succeed Eric Prengel.
Eric Prengel, who has served as the Interim Chief Financial Officer of the Company since December 14, 2024, will cease to serve in this role on February 28, 2025 upon the effectiveness on that date of the appointment of Navam Welihinda as the Company’s Chief Financial Officer
On February 23, 2025, Innovation1 Biotech Inc. (the “Company”) appointed Samuel Knipper to serve as chief financial officer of the Company.
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
David Lazar, the Company’s interim Chief Executive Officer, interim principal financial officer, interim principal accounting officer, and Secretary, provided notice of his resignation as Chief Executive Officer and Secretary of the Company effective February 26, 2025.
Datuk Dr. Doris Wong Sing Ee was also elected to the Board of the Company as of the effective date.
the Board appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role, she will serve as the Company’s principal executive officer.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.